PDCD1 and non-small cell lung carcinoma: AMBER (NCT02817633) part 2B assessed the safety and efficacy of cobolimab, an anti–TIM-3 humanized monoclonal antibody, plus PD-1 inhibitor dostarlimab in patients with locally advanced or metastatic NSCLC who had progressed on anti–PD-(L)1 treatment.